Purpose
Biliary obstruction due to advanced hepatic hilar malignancy is difficult to treat, both surgically and non-surgically, using endoscopic or percutaneous drainage. The resectability rates for hepatic hilar malignancies are generally reported to be approximately 10 to 20% (1, 2) , therefore treatment is palliative rather than curative in the vast majority of patients with hepatic hilar malignancies.
Percutaneous palliation of advanced hepatic hilar malignancies can be accomplished in a variety of ways. Although the necessity for drainage of both liver lobes is still controversial in Bismuth type II or higher malignant hilar tumors (3) (4) (5) (6) (7) (8) (9) , to preserve the functional volume of the liver in the course of chemotherapy and prevent procedure-related cholangitis of contaminated undrained lobe, bilateral drainage can be a reasonable option. Bilateral biliary drainage has been performed with placement of multiple stents via percutaneous or endoscopic approaches (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Although percutaneous stent-in-stent deployment technique with wide-mesh central portion has been introduced to facilitate passage of the second metallic stent during bilateral stenting (14) (15) (16) , less is known about the outcomes of this technique using open-cell-design stents in patients with malignant hilar biliary obstruction. Thus, the purpose of this study is to investigate the technical and clinical efficacy of percutaneous bilateral stent-in-stent deployment technique using wide-meshdesign and open-cell-design stents in patients with malignant hilar biliary obstruction and to compare the clinical outcomes of bilateral stent placement using T and Y configuration.
Methods and Materials
Patient Population From January 2006 to December 2010, 106 patients with malignant hilar biliary obstruction of Bismuth type II or higher were included in this study. Also definitive follow-up data was able to be obtained in all 106 patients. The patient characteristics are presented in Table. 1. The diagnosis was confirmed with pathologic specimens in 66 patients (62%) through percutaneous tranbiliary biopsy (n = 22) or endoscopic brushing cytology and biopsy (n = 44) and was presumed in the remaining 40 patients (38%) based on computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), and endoscopic retrograde cholangiopancreatography. Inclusion criteria were biliary hilar obstruction caused by hilar malignancy that could not be treated surgically as a result of unresectability, late-stage tumor, advanced age, or comorbid condition and an endoscopic attempt to drain the obstructed bile ducts were unsuccessful. Exclusion criteria included abnormal coagulation status (INR value #1.5 and platelet count #50,000), and poor general health status of the patients (Eastern Cooperative Oncology Group [ECOG] performance status grade [3] [4] . Technique Prior to percutaneous transhepatic biliary drainage (PTBD), CT or MRCP was performed to assess the anatomy and plan the most appropriate approach for intervention. All PTBD procedures were performed at the peripheral intrahepatic bile duct under conscious sedation using intravenous pethidine hydrochloride (Demerol, Keukdong Pharmaceuticals, Seoul, Korea) and local anesthesia using intramuscular injection of lidocaine (Jeil Pharmaceuticals, Taegu, Korea). The intrahepatic bile duct was punctured with a 21-gauge Chiba needle (Cook, Bloomington, IN, USA) under the guidance of fluoroscopy or ultrasonography, and an 8.5-F drainage catheter (Cook) was initially placed to relieve jaundice or cholangitis before insertion of the stent. Stent insertion was accomplished within two weeks after performing PTBD, allowing cholangitis, if present, to be treated. Antibiotics were administered intravenously 12 hours before the procedures and for at least 48 hours afterwards. Until September 2006, Niti-D stent with wide-mesh central portion (Kim stent; TaeWoong,Kimpo,Korea) ( Fig. 1 and 2) as a first stent, which was developed as a hybrid of spiral and Z stents was used in 15 consecutive patients. The mesh of the central portion was made larger by omitting the Z component, resulting in an 8-mm mesh size. The wide-mesh-design stent had a 6 to 8cm length and a fully expanded diameter of 10-mm. A second stent, Niti-D (TaeWoong) which had a 6 to 8cm length and a fully expanded diameter of 10 mm, was used via the central mesh of the first stent. These closed-cell-design stents were made of nitinol wire and come with an 8-F introducing system. These stents were available in Asia andEurope. After October 2006, commercially available open-cell-design stents (Zilver stent; Cook and Sentinol stent; Boston Scientific,Galway,Ireland) ( Fig. 3 and 4 ) as a first and second stent were used in subsequent 91 patients. The open-cell-design stents were made of nitinol with laser cutting, had high flexibility and minimal foreshortening during deployment, and come with 6-F introducing systems. The fully-expanded diameter of these stents was 10-mm for both stent types and the fully-expanded lengths were 6-cm or 8-cm for both stent types. The type of open-cell-design stent to be used was made by the physician operators according to their personal preference. Stent deployments were arranged in one of the following configurations: T configuration; bilateral stenting through a single percutaneous site via stent-in-stent deployment (n = 64). Y configuration; bilateral stenting through bilateral percutaneous sites via stent-in-stent deployment (n = 42). We initially attempted to perform T-configured bilateral drainage because it did not need additional contralateral puncture. However, in case in which negotiation of a guide wire into contralateral duct was not possible, Y-configured bilateral drainage was performed. T-configured bilateral drainage was achieved by using stent-in-stent deployment as follows. After contralateral duct negotiation with a 0.035-inch, 150-cm-long hydrophilic guide wire (Terumo, Tokyo, Japan) and a 5-F angled-tip catheter (Kumpe; Cook), dilation of the stricture was performed using a balloon catheter 6-8-mm in diameter (Cronus II; Medispes, Zug, Switzerland or Synergy; Boston Scientific) in all patients. A first stent was then deployed in the transverse direction. The guide wire left in place across the first stent was carefully withdrawn with an angled-tip catheter (Cook) and then introduced into the common bile duct (CBD) through the first stent mesh and stricture. The catheter was then removed over a 0.035-inch, 150-cm-long stiff hydrophilic guide wire (Terumo) or over an extra stiff Amplatz guide wire (Cook), and dilation of the first stent mesh and stricture was performed using a 6-8-mm angioplasty balloon catheter (Cronus II or Synergy) in all patients. A second stent was then deployed in the vertical direction. Y-configured bilateral drainage was achieved by using stent-in-stent deployment as follows ( Fig. 5-8 ). After CBD negotiation with a 0.035-inch, 150-cm-long hydrophilic guide wire (Terumo) and a 5-F angled-tip catheter (Kumpe; Cook), dilation of the stricture was performed using a balloon catheter 6-8-mm in diameter (Cronus II or Synergy) in all patients. A first stent was then deployed in the vertical direction. Another guide wire (Terumo) with an angled-tip catheter (Cook) from the contralateral bile duct was introduced into the CBD through the first stent mesh and stricture. The catheter was then removed over a 0.035-inch, 150-cm-long stiff hydrophilic guide wire (Terumo) or over an extra stiff Amplatz guide wire (Cook), and dilation of the first stent mesh and stricture was performed using a 6-8-mm angioplasty balloon catheter (Cronus II or Synergy) in all patients. A second stent was then deployed in the vertical direction. After stent placement, one or two 8.5-F or 10-F temporary drainage catheter(s) (Cook) was (were) placed just proximal to the stent(s). Thereafter, during 1-2 days of external drainage, frequent catheter irrigations were performed for the removal of possible blood clot or sludge. We then removed the temporary drainage catheter(s) after 2-3 days of catheter clamping without further intervention if free contrast flow through the stents into the CBD and the duodenum was documented. Study Endpoints and Definitions Major study endpoints were the assessment of technical success, complications, successful internal drainage, stent patency, and patient survival. Technical success was defined as stent deployment in an adequate position across the stricture with good contrast passage through the stents. Complications were classified as major and minor according to the guidelines of the Society of Interventional Radiology Standards of Practice Committee (20) . Minor complications were defined as those requiring no therapy or nominal therapy, including overnight admission for observation only. Major complications were defined as those necessitating major therapy, those necessitating an unplanned increase in the level of care or prolonged hospitalization (>48 hours), and those resulting in permanent adverse sequelae or death. Successful internal drainage was defined as successful removal of temporary drainage catheter(s) and a decrease of the serum bilirubin level to less than 75% of the pretreatment value within the first month following the stent placement. Stent occlusion was defined as biliary obstruction confirmed either endoscopically or radiologically plus laboratory results (elevated serum bilirubin levels more than 3 mg/ dl) as well as any condition requiring reintervention to improve biliary drainage. Tumor ingrowth was defined as tissue occluding the stent lumen and which could not be cleared by biliary balloon sweeping. Tumor overgrowth was defined as new stricture(s) occurring at the proximal or distal end of a stent. Sludge formation was defined as sludge occluding the stent lumen which could be cleared by biliary balloon sweeping. Stent patency time was defined as the time interval between the initial stent placement and stent occlusion. If there was no evidence of obstruction during a patient's lifetime, the patency period was considered equal to the patient survival time. Patient survival time was defined as the time interval between initial stent placement and the patient's death. Statistical Analysis Statistical analysis was conducted using SPSS software (version 14.0; SPSS, Chicago, IL). Mann-Whitney U test was used to compare pairs of independent, continuous variable between the groups. Fisher's exact test was used to compare categorical variables between the groups. A paired-sample t-test was used for preprocedural and postprocedural serum bilirubin level comparison. The stent patency and patient survival rates were calculated according to the Kaplan-Meier method, and the two groups were compared using the log rank test. Statistical significance was reached when P values were less than .05. Figure 6 . A 48-year-old man with hilar cholangiocarcinoma (Bismuth type III). After negotiating the guide with into CBD, the first Zilver stent from right side was deployed. 
Results
Bilateral stent deployment was technically successful in all patients. Fifteen patients received the wide-mesh-design stents as first stents and closed-cell-design stents as second stents, whereas the remaining 91 patients received open-cell-design stents as first and second stents, including 112 Sentinol and 70 Zilver stents. Patients' characteristics and outcomes in the two groups are shown in Table 2 . The T configuration was used in 64 patients and the Y configuration in 42; patient characteristics and outcomes in these two groups are shown in Table 3 . Procedure-related minor complications occurred in 11 patients (10.4%), including 7 with self-limiting hemobilia that completely resolved within 3 days without transfusion and 4 with cholangitis, which was rapidly resolved within 4 days by antibiotic treatment alone. There were no significant between group differences in complication rates Major complications occurred in three patients (2.8%). One patient had severe hemobilia secondary to a pseudoaneurysm of the left intrahepatic artery and was treated successfully with selective transarterial embolization. Two patients had acute cholecystitis and underwent percutaneous transhepatic gallbladder drainage. No major complications were directly related to the stent placement procedure. Follow-up cholangiography 3 to 5 days after stent placement showed adequate decompression of the biliary ducts in all patients. The temporary drainage catheters were removed from 101 patients (95.3%) after confirmation of good stent patency; the catheters could not be removed from the other 5 patients due to increased serum bilirubin levels caused by rapid disease progression. The mean serum bilirubin level, which was 13.5 mg/dl ± 7.6 before drainage, decreased significantly, to 1.7 mg/dl ± 1.3, one month after stent placement (p < 0.001). Successful internal drainage was achieved in 94 (88.7%) of 106 patients, including 57 of the 64 patients (89%) in the T-configured stent group and 37 of 42 (88%) in the Y-configured stent group (p > 0.999). Moreover, successful internal drainage was achieved by all 15 patients who received wide-mesh-design (100%) and 86 of 91 (87%) who received open-cell-design stents (p = 0.209). Clinical follow-up until death or the end of the study was available for all patients and the cutoff date for data analysis was April 30, 2011. The mean followup period was 224 days (range, 23-562 days) after placement of the stents. At the time of this analysis seven patients are still alive. Two patients (1.9%) had died within 30 days after stent placement in the T-configured stent group using open-cell-design stents. In these patients, death was caused by rapidly progressed underlying malignancy and was not directly related to the procedure. According to the Kaplan-Meier analysis, median patient survival was 192 days (95% CI, 153.6-230.4 days) (Fig 3) . There was no significant difference in the patient survival (p = 0.809), with median survival being 183 days in wider-mesh-design stent group and 203 days in open-cell-design stent group, and no significant difference in the patient survival (p = 0.970), with median survival being 184 days in T-configured stent group and 203 days in Y-configured stent group (Fig 4) . Stent occlusions caused by tumor ingrowth with/without tumor overgrowth occurred in 37 patients (34.9%) (five of 15 patients in wide-mesh-design stent group and in 32 of 91 patients in open-cell-design stent group; 22 of 64 patients in T-configured stent group and in 15 of 42 patients in Y-configured stent group). Stent occlusions were managed with PTBD (n = 36) or endoscopic biliary stent placement (n = 1). In 36 patients who underwent PTBD, bilateral drainage with one drainage catheter was possible in 20 of 22 patients in T-configured stent group and in six of 15 patients in Y-configured stent group. Additional contralateral PTBD was performed in 11 patients because guide wire negotiation into the contralateral duct was impossible due to severe tumor ingrowth and extensive tumor overgrowth. Percutaneous placement of open-cell-design stents was performed in two patients with stent occlusion caused by tumor ingrowth, after which good internal drainage was maintained for 3.5 and 4.5 months, respectively, before patients died. In the remaining 34 patients, additional stent placement was not performed due to disease progression and poor general health status of the patients. According to the Kaplan-Meier analysis, the median stent patency time was 319 days (95% CI, 148.5-489.5 days) ( Fig 5) . There was no significant difference in the stent patency (p = 0.550), with median patency being 319 days in wider-mesh-design stent group and 244 days in open-cell-design stent group, and no significant difference in the stent patency (p = 0.927), with median patency being 319 days in T-configured stent group and 497 days in Y-configured stent group (Fig 6) . Stent occlusion occurred in 37 patients (35%). Table 3 . Comparison of characteristics and outcomes of T-configured and Yconfigured groups Fig. 9: Figure 9 . Kaplan-Meier curve of the survival rate of the study patients. 
Conclusion
There have been conflicting opinions about whether stent placement should be unilateral or bilateral (3) (4) (5) (6) (7) (8) (9) . Some investigators have preferred bilateral stenting not only because unilateral stenting alone may not completely relieve jaundice (7) and may induce acute cholangitis (8) but also because stent patency may be longer than with unilateral stenting (9) . Moreover, bilateral drainage was associated with the best survival rate, and the worst survival rate was found among patients with cholangiographic opacification of both lobes but drainage of only one (7) . Other investigators, however, have advocated unilateral drainage not only because the risk of complications is lower than with multiple stent deployment (5) but also because adequate palliation can be achieved with drainage of only 25% of the liver (21) . Therefore, a single biliary stent into one functional liver lobe for unilateral drainage may provide adequate palliation in a major portion of patients with malignant hilar biliary obstruction. Sometimes, however, bilateral biliary stents may be the best option for palliative drainage of both liver lobes when both sides are contaminated or if chemotherapy is scheduled.
There are two techniques for percutaneous placement of bilateral metallic stents including a side-by-side stent deployment and a stent-in-stent deployment technique. The sideby-side stent deployment technique is a percutaneous procedure for bilateral metallic stenting with simultaneous delivery of two parallel metallic stents to drain the bile ducts of both hepatic lobes. However, the use of metallic stents in a parallel arrangement may prevent their full expansion at and below the hepatic confluence (14) . Although adequate drainage may be achieved, the stents open to less than their full diameter resulting in elongation of the stents or partial stent collapse of one or both stents. On the other hand, the stent-in-stent deployment technique is an alternative percutaneous procedure that allows bilateral metallic stenting to be placed in which a second stent traverse through the mesh of the first stent to enter the CBD. With this technique, the whole length of the stricture is continuously expanded within a single stent caliber which cannot be achieved using the side-by-side stent deployment technique. Moreover, with overlapping of the two stents, displacement of the stents can effectively be prevented (14, 15) . However, attempts to pass a second metallic stent through the mesh of the first stent can be technically problematic if the first stent is tightly weaving close-cell-design stent (22) .
To overcome the technical difficulty with the stent-in-stent deployment technique using closed-cell-design stents, in this study, we adopted two types of metallic stents (opencell-design and wide-mesh-design stents) as first stent and determined that all of the stents were preferable to bilateral stent-in-stent deployment. The cells of an open-celldesign stents used in this study are simply connected, compared with tight weaving or even interlocking of other closed-cell-design stents. Thus, open-cell-design stents are dilated easily by ballooning and stay in the dilated state. These characteristics permit easy passage of the second stent during bilateral stenting and its wide expansion. The wide-mesh-design stent used in this study has wider central mesh portion to permit easy passage of the delivery system for the second stent, which seems to cause an increased tendency of tumor ingrowth and to make the stent patency shorter. However, although a relatively small number of patients in the wide-mesh-design stent group were included in this study, there were no significant differences in the stent occlusion rate and stent patency period between the two stent groups even though the two stents had a different cell design. Moreover, there were no significant differences in technical success, complications, successful internal drainage, and patient survival between the wide-meshdesign stent and the open-cell-design stent group. We found that technical success rate (100%), complication rate (13.2%), and successful internal drainage rate (88.7%) of this study are in concordance with the results of other studies involving percutaneous bilateral metallic stent placement in patients with advanced hilar malignancies, i.e. technical success rate; range 93-100%, overall complications; range 17-33%, successful drainage; range 89-92%, (3, 11, 12) . The median patient survival time of 192 days is similar to the 176-247 days reported in previous studies (3, (15) (16) (17) (18) (19) . Although we do not know the exact reason why the median stent patency time is much longer than those of another two studies in which percutaneous bilateral stent-in-stent placement using the T configuration (median, 170 days) (15) and X configuration (median, 187 days) (16) , which had a wide-mesh-design stent as a first stent, the median stent patency time of this study is 319 days.
We also found that there were no significant differences in technical success (p > 0.999), complications (p = 0.338), successful internal drainage (p > 0.999), stent patency (p = 0.927), and patient survival (p = 0.970) between the T-and Y-configured stent groups. In this study, to achieve bilateral drainage in patients with stent occlusion, reintervention for an occluded stent inserted in a T configuration was much easily performed via a single percutaneous route than reintervention for an occluded stent inserted in a Y configuration. Additional contralateral PTBD was needed in two of 22 patients in T-configured stent group, however, needed in nine of 15 patients in Y-configurated stent group. Therefore, although we did not observe complications related to additional contralateral PTBD for Y-configured stent deployment, T-configured stent-in-stent deployment for bilateral drainage is preferable in patients with malignant hilar biliary obstruction unless technical difficulty necessitates Y-configurated stent-in-stent deployment.
In conclusion, percutaneous bilateral stent-in-stent placement using a wide-mesh-design or open-cell-design stents is feasible and effective method to achieve bilateral drainage in patients with malignant hilar biliary obstruction. Moreover, T-configured stent-instent deployment for bilateral drainage is preferable in patients with malignant hilar biliary obstruction unless technical difficulty necessitates Y-configurated stent-in-stent deployment.
